FILE - This June 30, 2011, file photo, shows the Eli Lilly and Company corporate headquarters in Indianapolis. Eli Lilly said Wednesday, Nov. 23, 2016, that its potential Alzheimer’s treatment, solanezumab, failed in another large clinical study, ending hope that researchers had finally found a drug that can slow the fatal, mind-robbing disease. (AP Photo/Darron Cummings, File)
